ImClone stock dived 8 percent this morning when researchers announced that a late-stage trial of Erbitux as a first-line therapy for advanced lung cancer flunked its primary endpoint of progression-free survival as assessed by an independent radiology review committee. Researchers, though, put the best spin on the data that they could, noting that secondary endpoints--including response rate--"were statistically significant and favored the Erbitux-containing arm."
"We consider lung cancer to be a high priority and await the results of other Phase II and Phase III evaluations of ERBITUX in the first- and second- line setting with chemotherapy regimens," said ImClone medical chief Eric K. Rowinsky.
- for more on the data, see the release [1]
- read TheStreet.com report [2] on ImClone
Related Articles:
Erbitux data underscores leaked disappointment. Report [3]
ImClone buoyed by new Erbitux data. Report [4]
Erbitux data could gin extra $350M in sales. Report [5]
Analysts raise doubts on Erbitux ruling. Report [6]
ImClone touts survival rate in Erbitux cancer trial. Report [7]
Links:
[1] http://www.fiercebiotech.com/node/7603
[2] http://www.thestreet.com/s/study-sinks-imclone-shares/newsanalysis/biotech/10367470.html?puc=_googlen?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[3] http://www.fiercebiotech.com/story/erbitux-data-underscores-leaked-disappointment/2007-06-04
[4] http://www.fiercebiotech.com/story/imclone-buoyed-by-new-erbitux-data/2007-04-17
[5] http://www.fiercebiotech.com/story/erbitux-data-could-gin-extra-350m-in-sales/2007-04-05
[6] http://www.fiercebiotech.com/story/analysts-raise-doubts-on-erbitux-ruling/2006-09-20
[7] http://www.fiercebiotech.com/story/imclone-touts-increased-survival-rate-in-erbitux-cancer-trial/2005-11-16